Understand the source comparison
Mod GRF 1-29 vs CJC-1295 with DAC: Structural and Functional Comparison
The table below clarifies the structural, pharmacokinetic, and research-context distinctions between Mod GRF 1-29 and CJC-1295 with DAC. Peptides frequently conflated in research documentation despite producing fundamentally different growth hormone dynamics.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below clarifies the structural, pharmacokinetic, and research-context distinctions between Mod GRF 1-29 and CJC-1295 with DAC. Peptides frequently conflated in research documentation despite producing fundamentally different growth hormone dynamics.
- Structural composition
- 29-amino-acid peptide with 4 substitutions for DPP-IV resistance
- Mod GRF 1-29 covalently bonded to Drug Affinity Complex (DAC)
- DAC extends half-life by binding serum albumin. Not a trivial modification
- Plasma half-life
- ~30 minutes
- 6–8 days
- 300× difference. This changes everything about experimental design
- GH release pattern
- Single pulse lasting 2–3 hours, returns to baseline
- Sustained elevation for 6–10 days after single dose
- Pulsatile vs continuous. Fundamentally different physiological states
- IGF-1 response per unit GH
- Higher due to pulse-frequency dependence
- Lower due to GH receptor downregulation from sustained exposure
- Pulsatile delivery produces more IGF-1 per ng of GH released
- Dosing frequency
- 1–3× daily (protocol-dependent)
- Once every 5–7 days
- Frequency reflects pharmacokinetics, not potency
- Circadian rhythm preservation
- Yes. Does not suppress endogenous GHRH
- No. Negative feedback suppresses endogenous pulses
- Critical for sleep, metabolic, and circadian research
- Professional Assessment
- Preferred for protocols requiring physiological pulsatile GH release, circadian preservation, or long-term use without tachyphylaxis
- Appropriate for sustained GH elevation models; risk of receptor desensitization in protocols >12 weeks
- Use Mod GRF 1-29 unless research explicitly requires continuous GH elevation